Wet age-related macular degeneration (wet AMD) is a progressive eye disease in which abnormal, fragile blood vessels grow under the macula and leak fluid or blood, leading to irreversible central vision loss if not treated. In many patients, untreated wet AMD can progress to legal blindness within months to a few years. Wet AMD primarily affects older adults, with prevalence rising steeply with ag...
Wet age-related macular degeneration (wet AMD) is a progressive eye disease in which abnormal, fragile blood vessels grow under the macula and leak fluid or blood, leading to irreversible central vision loss if not treated. In many patients, untreated wet AMD can progress to legal blindness within months to a few years. Wet AMD primarily affects older adults, with prevalence rising steeply with age. Recent analyses suggest that approximately 1–3% of individuals aged 75 years and older are affected, with hundreds of thousands of patients living with wet AMD in the US alone and substantial numbers of new diagnoses each year (1-3). As populations age, the overall burden of wet AMD is expected to increase further over the coming decades. The current standard of care for wet AMD is based on intravitreal anti-VEGF therapies. These often require 6–10 injections in the first year, followed by ongoing injections in subsequent years, resulting in a long-term treatment burden for patients. Beyond the risk of complications from frequent injections, this regimen places significant pressure on healthcare services and on patients with their caregivers who must attend regular, time-consuming clinic visits. Despite intensive treatment, an estimated 25–35% of patients with more aggressive disease have partial or inadequate responses and remain at risk of progressive, irreversible vision loss. Given these limitations, there is a strong unmet need for more durable, disease-modifying therapies. A broad R&D pipeline is investigating new molecular targets and innovative delivery technologies, including gene therapies designed to drive long-term intraocular expression of anti-VEGF or VEGF-targeting molecules. Gene therapies could thereby reduce or eliminate the need for repeated injections. Later-stage (pivotal Phase 3) AAV-based gene therapy candidates include 4D-150 (4D Molecular Therapeutics), ABBV-RGX-314 (sura-vec, Regenxbio/AbbVie) and ADVM-022 (ixo-vec, Adverum). These candidates ha...
Explore the exciting world of Cadence Design Systems (NASDAQ: CDNS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Dec. 10, 2025. The video was published on Jan. 26, 2026. Should you buy stock in Cadence Design Systems r...
Explore the exciting world of Cadence Design Systems (NASDAQ: CDNS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Dec. 10, 2025. The video was published on Jan. 26, 2026. Should you buy stock in Cadence Design Systems right now? Before you buy stock in Cadence Design Systems, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cadence Design Systems wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $464,439!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,150,455!* Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of January 26, 2026. Anand Chokkavelu has no position in any of the stocks mentioned. Jason Hall has no position in any of the stocks mentioned. Rick Munarriz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cadence Design Systems. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Enterprise Financial Services Corp. (EFSC) released a profit for its fourth quarter that Increases, from the same period last year in line with the Street estimates. The company's bottom line came in at $53.86 million, or $1.45 per share. This compares with $47.90 million, or $1.28 per share, last year. Excluding items, Enterprise Financial Services Corp. reported adjusted earnings of ...
(RTTNews) - Enterprise Financial Services Corp. (EFSC) released a profit for its fourth quarter that Increases, from the same period last year in line with the Street estimates. The company's bottom line came in at $53.86 million, or $1.45 per share. This compares with $47.90 million, or $1.28 per share, last year. Excluding items, Enterprise Financial Services Corp. reported adjusted earnings of $1.36 per share for the period. Analysts on average had expected the company to earn $1.36 per share. Analysts' estimates typically exclude special items. The company's revenue for the period rose 15.9% to $193.58 million from $167.00 million last year. Enterprise Financial Services Corp. earnings at a glance (GAAP) : -Earnings: $53.86 Mln. vs. $47.90 Mln. last year. -EPS: $1.45 vs. $1.28 last year. -Revenue: $193.58 Mln vs. $167.00 Mln last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
It doesn't look like the company will end up in the arms of an acquirer soon, after all. Monday was generally a good day for the stock market; nevertheless, some titles landed in negative territory. One that plunged well into the red was clinical-stage biotech Revolution Medicines (RVMD 16.88%), which took a nearly 17% hit to its share price after a media report published over the weekend. Buyout ...
It doesn't look like the company will end up in the arms of an acquirer soon, after all. Monday was generally a good day for the stock market; nevertheless, some titles landed in negative territory. One that plunged well into the red was clinical-stage biotech Revolution Medicines (RVMD 16.88%), which took a nearly 17% hit to its share price after a media report published over the weekend. Buyout blues On Sunday, The Wall Street Journal wrote that Merck was no longer in discussions with Revolution regarding an acquisition. Investors were understandably crushed by this apparent news, as hot speculation had it that the two companies were discussing a deal worth tens of billions of dollars. Citing unidentified "people familiar with the matter," the Journal said that the talks stalled after Revolution and Merck failed to agree on the price of a buyout. The financial newspaper's sources added that this isn't necessarily the end of Merck's pursuit, as the discussions between the two companies could resume. Merck is not the only enterprise reported to be interested in acquiring Revolution; earlier this month, the Journal wrote that AbbVie and other pharmaceutical companies were also in the hunt. AbbVie subsequently denied it was pursuing Revolution. Expand NASDAQ : RVMD Revolution Medicines Today's Change ( -16.88 %) $ -19.85 Current Price $ 97.78 Key Data Points Market Cap $23B Day's Range $ 92.50 - $ 99.51 52wk Range $ 29.17 - $ 124.49 Volume 10M Avg Vol 3.3M A prized and pricey asset I'd bet my bottom dollar that the speculation about multiple potential suitors is true. Revolution's specialty is the development of oncology drugs, which remains a very hot, high-interest segment of the pharmaceutical industry. What's more, the company's leading drug candidate, daraxonrasib, is currently in Phase 3 clinical trials for the treatment of pancreatic and non-small cell lung cancer. So even if Merck goes away completely, I think Revolution will sell for a handsome premium if it ...
Trump Threatens To Raise Tariffs On South Korean Goods To 25%; Won Slides Here we go again. President Trump threatened to hike tariffs on goods from South Korea to 25% from 15%, citing in a Truth Social post what he said was the failure of the country’s legislature to codify the trade deal the two nations reached last year, a failure which was obvious from miles away as the terms of the trade deal...
Trump Threatens To Raise Tariffs On South Korean Goods To 25%; Won Slides Here we go again. President Trump threatened to hike tariffs on goods from South Korea to 25% from 15%, citing in a Truth Social post what he said was the failure of the country’s legislature to codify the trade deal the two nations reached last year, a failure which was obvious from miles away as the terms of the trade deal require Korea to invest hundreds of billions - which it doesn't have - in the US. The new rate would apply to autos, lumber, pharmaceutical products and “all other Reciprocal TARIFFS," he wrote in a social media post. It probably would not apply to memory chips which are already the most expensive thing on plant earth, at least until the RAM producing cartel starts to, well, producing RAM again. If implemented, the move could have wide-ranging effects on major South Korean companies that export to the US, such as Hyundai Motor, which sent 1.1 million vehicles to America in 2024. As Bloomberg notes, Trump’s announcement marks his latest move to ratchet up trade tensions with allies. In recent weeks, he has threatened to raise duties on Canadian products to 100% if Ottawa signed a trade deal with China (it then promptly said it would not) and to slap new charges on European countries’ goods over his quest to seize control of Greenland. The USDKRW gapped up 0.7% to 1452 on the news, amid thin liquidity before the local market open. Tyler Durden Mon, 01/26/2026 - 19:16
Pacific Investment Management Co. is holding fast to its conviction in Japan’s 30-year government bonds after last week’s rout, joining a growing pool of investors who see value in the nation’s debt market. Current yield levels present attractive investment opportunities, the money manager said. Last week, fears of fiscal excess by Prime Minister Sanae Takaichi’s administration wiped out $41 billi...
Pacific Investment Management Co. is holding fast to its conviction in Japan’s 30-year government bonds after last week’s rout, joining a growing pool of investors who see value in the nation’s debt market. Current yield levels present attractive investment opportunities, the money manager said. Last week, fears of fiscal excess by Prime Minister Sanae Takaichi’s administration wiped out $41 billion from the bond market and triggered a selloff elsewhere. Higher yields offer the potential for capital gains if interest rates fall and serve as a hedge against economic shocks, volatility in equities or a sharp appreciation in the yen, Pimco added. “We maintain a preference for the long-end of the curve, such as 30-year JGBs,” Tomoya Masanao, Pimco’s head of Asia-Pacific portfolio management, wrote in an outlook report . “While concerns about fiscal risks persist, the steepness of the yield curve and incentives for the Ministry of Finance to limit long-end issuance support this positioning.” The call mirrors the view of investors including Sumitomo Mitsui Financial Group Inc. and RBC BlueBay Asset Management , and suggests that investors have grown accustomed to gyrations in Japan’s bond market after years of accommodative policy kept yields pinned near zero. Traders are bracing for swings to pick up again after a period of calm, as the nation gears up for an election on Feb. 8 and talk of intervention buffets the yen. Pimco, one of the world’s biggest bond houses, was similarly optimistic about JGBs after a chaotic selloff in mid-2025. Back then, the money manager argued that the possibility of more quantitative tightening by the Bank of Japan could be a good thing, since it would relieve pressure on the long-end of the curve, where the central bank is less active. The money manager expects the BOJ to continue normalizing policy gradually and potentially raise the policy rate by a quarter to half a percentage point toward 1% to 1.25% over the coming year. The central ba...